Difference between revisions of "Template:Available forms of progesterone"

From blackwiki
Jump to navigation Jump to search
imported>CV9933
(tweak cite "Drugs@FDA" for transclusion)
imported>Medgirl131
(Further compact + improve appearance.)
Line 1: Line 1:
{| class="wikitable sortable floatright plainrowheaders" style="text-align:left; margin-left:auto; margin-right:auto; border:none; width:35%"
+
{| class="wikitable sortable floatright plainrowheaders" style="width:465px; font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;"
 
|+ class="nowrap" | {{Navbar|Available forms of progesterone|mini=y}} Available forms of [[progesterone (medication)|progesterone]]{{refn|group=sources|'''Sources:''' <ref name="Drugs@FDA">{{cite web |title=Drugs@FDA: FDA Approved Drug Products |publisher=United States Food and Drug Administration |accessdate=26 July 2018 |url=http://www.accessdata.fda.gov/scripts/cder/daf/}}</ref>
 
|+ class="nowrap" | {{Navbar|Available forms of progesterone|mini=y}} Available forms of [[progesterone (medication)|progesterone]]{{refn|group=sources|'''Sources:''' <ref name="Drugs@FDA">{{cite web |title=Drugs@FDA: FDA Approved Drug Products |publisher=United States Food and Drug Administration |accessdate=26 July 2018 |url=http://www.accessdata.fda.gov/scripts/cder/daf/}}</ref>
 
<ref name="EngelKleemann2014">{{cite book| vauthors = Engel J, Kleemann A, Kutscher B, Reichert D |title=Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs|url=https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1145|date=14 May 2014|publisher=Thieme|isbn=978-3-13-179275-4|pages=1145–}}</ref><ref name="Becker2001">{{cite book| first = Kenneth L. | last = Becker | name-list-format = vanc |title=Principles and Practice of Endocrinology and Metabolism |url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA2168|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=2168–}}</ref><ref name="MVJain2018">{{cite book| vauthors = Anita MV, Jain S, Goel N |title=Use of Progestogens in Clinical Practice of Obstetrics and Gynecology|url=https://books.google.com/books?id=VrpEDwAAQBAJ&pg=PA4|date=31 July 2018|publisher=JP Medical Ltd|isbn=978-93-5270-218-3|pages=4–}}</ref><ref name="Sauer2013">{{cite book | first = Mark V. | last = Sauer | name-list-format = vanc |title=Principles of Oocyte and Embryo Donation|url=https://books.google.com/books?id=LUpDAAAAQBAJ&pg=PA7|date=1 March 2013|publisher=Springer Science & Business Media|isbn=978-1-4471-2392-7|pages=7,117–118}}</ref><ref name="ElderDale2010">{{cite book| vauthors = Elder K, Dale B |title=In-Vitro Fertilization|url=https://books.google.com/books?id=JXV6eYd8RwwC&pg=PA26|date=2 December 2010|publisher=Cambridge University Press|isbn=978-1-139-49285-0|pages=26–}}</ref><ref name="P.R.-Vademecum-ProSphere">https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/</ref><ref name="Kahr2013">{{cite book|author=Heinrich Kahr|title=Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur|url=https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA21|date=8 March 2013|publisher=Springer-Verlag|isbn=978-3-7091-5694-0|pages=21–}}</ref><ref name="Schering1962">{{cite book|title=Basic Sex Hormone Therapy|url=https://books.google.com/books?id=uJrIvQEACAAJ|year=1962|publisher=Schering A.G.|page=96}}</ref><ref name="CurrMedDrugs1962">{{cite book|title=Current Medicine and Drugs|url=https://books.google.com/books?id=auc1AQAAIAAJ|year=1962|page=40|quote=Primolut Intravenous (Schering A.G. Berlin)}}</ref><ref name="HaleemKhan2015">{{cite journal | vauthors = Haleem S, Khan MI | title = Changing Indian Market Trends of NMP: A Review | journal = International Journal of Pharma Research & Review | volume = 4 | issue = 3 | pages = 28–30 | date = March 2015 | issn = 2278-6074 | url = https://web.archive.org/web/20200819053823/https://pdfs.semanticscholar.org/a232/3b1d613fd8f767c35b81d74a302e779ed749.pdf}}</ref>}}{{efn|group=progforms|This table only includes products where progesterone is the sole active ingredient.}}
 
<ref name="EngelKleemann2014">{{cite book| vauthors = Engel J, Kleemann A, Kutscher B, Reichert D |title=Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs|url=https://books.google.com/books?id=4lCGAwAAQBAJ&pg=PA1145|date=14 May 2014|publisher=Thieme|isbn=978-3-13-179275-4|pages=1145–}}</ref><ref name="Becker2001">{{cite book| first = Kenneth L. | last = Becker | name-list-format = vanc |title=Principles and Practice of Endocrinology and Metabolism |url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA2168|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=2168–}}</ref><ref name="MVJain2018">{{cite book| vauthors = Anita MV, Jain S, Goel N |title=Use of Progestogens in Clinical Practice of Obstetrics and Gynecology|url=https://books.google.com/books?id=VrpEDwAAQBAJ&pg=PA4|date=31 July 2018|publisher=JP Medical Ltd|isbn=978-93-5270-218-3|pages=4–}}</ref><ref name="Sauer2013">{{cite book | first = Mark V. | last = Sauer | name-list-format = vanc |title=Principles of Oocyte and Embryo Donation|url=https://books.google.com/books?id=LUpDAAAAQBAJ&pg=PA7|date=1 March 2013|publisher=Springer Science & Business Media|isbn=978-1-4471-2392-7|pages=7,117–118}}</ref><ref name="ElderDale2010">{{cite book| vauthors = Elder K, Dale B |title=In-Vitro Fertilization|url=https://books.google.com/books?id=JXV6eYd8RwwC&pg=PA26|date=2 December 2010|publisher=Cambridge University Press|isbn=978-1-139-49285-0|pages=26–}}</ref><ref name="P.R.-Vademecum-ProSphere">https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/</ref><ref name="Kahr2013">{{cite book|author=Heinrich Kahr|title=Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur|url=https://books.google.com/books?id=Hte1BgAAQBAJ&pg=PA21|date=8 March 2013|publisher=Springer-Verlag|isbn=978-3-7091-5694-0|pages=21–}}</ref><ref name="Schering1962">{{cite book|title=Basic Sex Hormone Therapy|url=https://books.google.com/books?id=uJrIvQEACAAJ|year=1962|publisher=Schering A.G.|page=96}}</ref><ref name="CurrMedDrugs1962">{{cite book|title=Current Medicine and Drugs|url=https://books.google.com/books?id=auc1AQAAIAAJ|year=1962|page=40|quote=Primolut Intravenous (Schering A.G. Berlin)}}</ref><ref name="HaleemKhan2015">{{cite journal | vauthors = Haleem S, Khan MI | title = Changing Indian Market Trends of NMP: A Review | journal = International Journal of Pharma Research & Review | volume = 4 | issue = 3 | pages = 28–30 | date = March 2015 | issn = 2278-6074 | url = https://web.archive.org/web/20200819053823/https://pdfs.semanticscholar.org/a232/3b1d613fd8f767c35b81d74a302e779ed749.pdf}}</ref>}}{{efn|group=progforms|This table only includes products where progesterone is the sole active ingredient.}}
 
|-
 
|-
! scope="col" style="width:100px;" | Route/form
+
! scope="col" | Route/form
! scope="col" style="width:80px;" | Dose
+
! scope="col" | Dose
! scope="col" style="width:80px;" | Brand name
+
! scope="col" | Brand name
! scope="col" style="width:80px;" | Availability{{efn|group=progforms|See also: [[Progesterone (medication)#Availability|Progesterone (medication) § Availability]]}}
+
! scope="col" | Availability{{efn|group=progforms|See also: [[Progesterone (medication)#Availability|Progesterone (medication) § Availability]]}}
 
|-
 
|-
 
! scope="row" style="background:#f8f9fa;" | [[Oral administration|Oral]] capsule
 
! scope="row" style="background:#f8f9fa;" | [[Oral administration|Oral]] capsule
Line 27: Line 27:
 
|-
 
|-
 
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] gel
 
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] gel
| 4%, 8% (45, 90&nbsp;mg) || Crinone{{efn|group=progforms|name=others}} || Widespread
+
| 4, 8% (45, 90&nbsp;mg) || Crinone{{efn|group=progforms|name=others}} || Widespread
 
|-
 
|-
 
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] suppository
 
! scope="row" style="background:#f8f9fa;" | [[Vaginal administration|Vaginal]] suppository
Line 44: Line 44:
 
| 2,&nbsp;5,&nbsp;10,&nbsp;20,&nbsp;25,<br />50,&nbsp;100&nbsp;mg/mL || Proluton{{efn|group=progforms|name=others}} || Widespread
 
| 2,&nbsp;5,&nbsp;10,&nbsp;20,&nbsp;25,<br />50,&nbsp;100&nbsp;mg/mL || Proluton{{efn|group=progforms|name=others}} || Widespread
 
|-
 
|-
! scope="row" style="background:#f8f9fa;" | IM ({{abbr|aq.|aqueous}} suspension)
+
! scope="row" style="background:#f8f9fa;" | IM ({{abbr|aq. susp.|aqueous suspension}})
| 12.5, 30, 100&nbsp;mg/mL || Agolutin{{efn|group=progforms|name=others}} || Europe{{efn|group=progforms|Specifically the Czech Republic and Slovakia.}}
+
| style="font-size: 90%;" | 12.5, 30, 100&nbsp;mg/mL || Agolutin{{efn|group=progforms|name=others}} || Europe{{efn|group=progforms|Specifically the Czech Republic and Slovakia.}}
 
|-
 
|-
 
! scope="row" style="background:#f8f9fa;" | IM (emulsion)
 
! scope="row" style="background:#f8f9fa;" | IM (emulsion)

Revision as of 14:40, 2 October 2020

Available forms of progesterone[sources 1][lower-alpha 1]

Route/form Dose Brand name Availability[lower-alpha 2]
Oral capsule 100, 200, 300 mg Prometrium[lower-alpha 3] Widespread
Oral tablet (SR) 200, 300, 400 mg Dubagest SR[lower-alpha 3] India
Sublingual tablet 10, 25, 50, 100 mg Luteina[lower-alpha 3] Europe[lower-alpha 4]
Transdermal gel[lower-alpha 5] 1% (25 mg) Progestogel Europe
Vaginal capsule 100, 200 mg Utrogestan Widespread
Vaginal tablet 100 mg Endometrin[lower-alpha 3] Widespread
Vaginal gel 4, 8% (45, 90 mg) Crinone[lower-alpha 3] Widespread
Vaginal suppository 200, 400 mg Cyclogest Europe
Vaginal ring 10 mg/day[lower-alpha 6] Fertiring[lower-alpha 3] South America[lower-alpha 7]
Rectal suppository 200, 400 mg Cyclogest Europe
Intrauterine device 38 mg Progestasert Discontinued
IM (oil solution) 2, 5, 10, 20, 25,
50, 100 mg/mL
Proluton[lower-alpha 3] Widespread
IM (aq. susp.) 12.5, 30, 100 mg/mL Agolutin[lower-alpha 3] Europe[lower-alpha 8]
IM (emulsion) 5, 10, 25 mg/mL Di-Pro-Emulsion Discontinued
IM (microsphere) 20, 100 mg/mL ProSphere[lower-alpha 3] Mexico
SC (aq. solution) 25 mg/vial Prolutex Europe
SC implant 50, 100 mg Proluton[lower-alpha 3] Discontinued
IV (aq. solution) 20 mg/mL Primolut Discontinued
Sources and footnotes:
  1. This table only includes products where progesterone is the sole active ingredient.
  2. See also: Progesterone (medication) § Availability
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 Other brand names exist.
  4. Specifically in Poland and Ukraine.
  5. For local application to the breasts; negligible systemic effect.
  6. One progesterone vaginal ring provides 10mg of progesterone each day for 3 months.
  7. Specifically in Chile, Ecuador, and Peru.
  8. Specifically the Czech Republic and Slovakia.
Template documentation

See also

References

  1. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
  2. Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
  3. Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
  4. Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
  5. Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
  6. Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
  7. https://web.archive.org/web/20191230051017/https://mx.prvademecum.com/medicamento/prosphere-11003/
  8. Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
  9. Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
  10. Current Medicine and Drugs. 1962. p. 40. Primolut Intravenous (Schering A.G. Berlin)
  11. Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074.